HEALTHJul 31 · 12:32 UTCSTAT NEWSElaine Chen

STAT+: Novo Nordisk inflammation-targeting drug misses mark in heart disease study

Novo Nordisk's investigational drug ziltivekimab failed to reduce major heart events in a Phase 3 trial involving over 6,300 participants with heart disease, kidney disease, and inflammation, despite lowering inflammation markers. The company's shares fell about 7% following the announcement.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Novo Nordiskorganizationziltivekimabtopicheart diseasetopickidney diseasetopicinflammationtopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHJul 31 · 12:50 UTC
Novo Nordisk stock sinks after anti-inflammatory heart drug fails late-stage trial
BUSINESSJul 31 · 12:07 UTC
Novo Nordisk shares dive after heart medicine fails trial
HEALTHJul 9 · 09:13 UTC
STAT+: AstraZeneca, Ionis report major trial failure with heart disease drug
HEALTHJun 22 · 21:36 UTC
STAT+: Closely watched Pfizer lung cancer drug falls short in clinical trial
HEALTHJul 23 · 10:45 UTC
STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit